ICU Medical (NASDAQ:ICUI) Given New $172.00 Price Target at Piper Sandler

ICU Medical (NASDAQ:ICUI) had its price target hoisted by Piper Sandler from $153.00 to $172.00 in a research report released on Friday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Several other equities analysts also recently weighed in on ICUI. Raymond James Financial decreased their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. KeyCorp lowered their target price on ICU Medical from $191.00 to $173.00 and set an “overweight” rating on the stock in a report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

ICU Medical Price Performance

Shares of NASDAQ ICUI traded up $10.49 during midday trading on Friday, hitting $140.16. The stock had a trading volume of 838,675 shares, compared to its average volume of 270,664. The company has a market capitalization of $3.46 billion, a PE ratio of -92.21 and a beta of 0.83. The stock has a 50 day simple moving average of $124.12 and a 200-day simple moving average of $128.22. ICU Medical has a 1 year low of $107.00 and a 1 year high of $196.26. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, topping the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, sell-side analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain bought 21,929 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares of the company’s stock, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David C. Greenberg purchased 1,200 shares of the firm’s stock in a transaction on Wednesday, August 27th. The shares were purchased at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the purchase, the director directly owned 7,960 shares of the company’s stock, valued at $1,006,303.20. This represents a 17.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On ICU Medical

Hedge funds have recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new stake in ICU Medical during the 1st quarter worth approximately $479,000. Vident Advisory LLC purchased a new stake in shares of ICU Medical during the first quarter worth $270,000. Envestnet Asset Management Inc. raised its stake in shares of ICU Medical by 8.2% in the first quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier’s stock valued at $2,815,000 after acquiring an additional 1,534 shares in the last quarter. Simon Quick Advisors LLC acquired a new stake in shares of ICU Medical in the second quarter valued at $275,000. Finally, Woodline Partners LP boosted its holdings in ICU Medical by 31.6% in the first quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock valued at $22,344,000 after purchasing an additional 38,671 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.